Guardant Health, Inc. 8-K

What Happened
Guardant Health, Inc. held its Annual Meeting on June 17, 2026 and filed the voting results on Form 8‑K (filed June 18, 2026). All director nominees listed in the company’s proxy were elected. Key votes: Ian Clark received 70,526,891 votes for (37,916,548 withheld; 7,714,711 broker non‑votes); Manuel Hidalgo Medina received 81,925,123 votes for (26,518,316 withheld; 7,714,711 broker non‑votes). Shareholders ratified Deloitte & Touche LLP as the independent auditor for the year ending December 31, 2026 (115,899,030 for; 15,250 against; 243,870 abstentions). The advisory (non‑binding) vote on named executive officer compensation ("say‑on‑pay") was not approved (98,236,639 for; 9,905,190 against; 301,610 abstentions; 7,714,711 broker non‑votes). Shareholders also voted on the frequency of future advisory compensation votes, with the one‑year option receiving the most votes (107,997,996 for one year).

Key Details

• Annual Meeting date: June 17, 2026; 8‑K filed June 18, 2026.
• Director election totals: Ian Clark — 70,526,891 for; Manuel Hidalgo Medina — 81,925,123 for.
• Auditor ratification: Deloitte & Touche LLP approved (115,899,030 for).
• Advisory compensation vote: say‑on‑pay not approved (98,236,639 for vs. 9,905,190 against); advisory vote frequency favored annual votes (107,997,996 for one year).

Why It Matters
These voting outcomes confirm the board slate and auditor for 2026, providing continuity in governance and external audit oversight. The failure of the non‑binding say‑on‑pay vote indicates significant shareholder concern about executive compensation — a governance signal investors and the company typically monitor closely. The one‑year frequency result means shareholders prefer annual advisory votes on pay. While the say‑on‑pay vote is advisory (non‑binding), it can prompt company engagement with investors and potential review of compensation policies.